At a glance
ClinicalIndex Comparison RecordN/ACompleted· 471 enrolled
Drug / intervention
I-123 mIBGdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup
In Brief
An observational study evaluating I-123 mIBG for Congestive Heart Failure. Completed, enrolled 471 participants across 1 site.
Detailed Summary
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedNov 2008
Primary CompletionJan 2010
Study CompletionFeb 2010
TodayJul 2026
First PostedNov 5, 2008
Enrollment StartMay 1, 2008
Primary CompletionJan 1, 2010
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.7 years ago
Interventions
I-123 mIBGdrug
This was an observational study. Participants were previously dosed in separate study.